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ABSTRACT
Objectives: The main aims of the study were to investigate the expression of vimentin and its correlation with the overall 
survival (OS) of patients with malignant ovarian tumors, and the correlation between vimentin expression and tumor 
stroma characteristics.
Material and methods: The study focused on 94 malignant ovarian tumors that had been collected from women who 
were treated in the Department of Gynecology and Oncology of the Lukaszczyk Oncological Center, Bydgoszcz, Poland. 
Vimentin expression was assessed in both the cancer cells (expression intensity and quantitative analysis) and the tumor 
stroma (expression intensity). Vimentin expression was analyzed according to both stromal cellularity and the clinicopatho-
logical features of the disease. 
Results: Both high cancer cell vimentin expression intensity and high quantitative vimentin expression (up to and includ-
ing 30% of cells) indicated a significantly prolonged OS. Low vimentin stromal expression was associated with prolonged 
OS, although the difference did not reach the level of significance. High tumor cell vimentin expression intensity was as-
sociated with significantly higher vimentin stromal expression. High vimentin expression in the tumor stroma indicated 
a significantly higher cellularity of the tumor stroma. Vimentin expression in cancer cells and the tumor stroma were not 
dependent on the histopathological type, the tumor grade or the FIGO stageof the disease. 
Conclusions: High cancer cell vimentin expression is associated with an improved OS of patients with malignant ovar-
ian tumors. The expression of vimentin in ovarian malignancies may influence the structure of the tumor stroma. 
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INTRODUCTION
Epithelial ovarian cancer (EOC) is the leading cause of 
death from gynecological malignancies as well as the fifth 
leading cause of cancer-related death among women in 
the Western countries. A woman’s lifetime risk of develop-
ing EOC is 1.3%, meaning that one in 78 women will be 
affected by EOC. Although complete remission following 
primary treatment is achieved in approximately one half of 
all patients, the majority of these patients will relapse, and 
the disease will then become fatal [1, 2]. 
Multiple factors influence the prognosisfor EOC pa-
tients. Patient overall survival (OS) is affected by the degree 
of residual disease following surgery, the histological type 
of the tumor, the type of first-line chemotherapy, the stage 
of the disease, and the age of the patient at diagnosis [3].
Until recently, cancer studies were mainly focused on the 
characteristics of the cancer cells themselves. However, 
it is now known that some features of the tumor stroma-
can impact patient OS. For example, in a study by Chen 
et al., patients with stroma-rich ovarian malignancies had 
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a worse prognosis and a higher risk of relapse compared 
with patients with tumors with poorly developed stroma [4]. 
Multiple stromal cells, such as cancer-associated fibroblast 
(CAFs), tumor-infiltrated lymphocytes (TILs), and tumor-as-
sociated macrophages (TAMs) secrete growth factors and 
immunomodulating cytokines that facilitate cancer progres-
sion. The development of new blood vessels enables tumor 
growth and may influence the cancer cell phenotype. The 
role of tumor stroma is especially important when it comes 
to cancer invasion and metastasis [5].Cancer cells can com-
municate with stromal cells and modify stromal architecture 
and cell content, creating a more permissive microenviron-
ment to facilitate its own growth [6]. Angiogenesis is one of 
the most important stromal targets for ovarian cancer ther-
apy. Anti-vascular-endothelial growth factor (VEGF) therapy 
has a well-established position in the primary treatment of 
non-optimally debulked ovarian cancer [7]. However, novel 
therapies targeting stromal cells, such as CAFs and TILs, are 
also being developed and applied [8–10].
Vimentin, a 57 kDa protein, is one of the cytoskeletal pro-
teins belonging to the type III intermediate filament protein 
family. Vimentin expression in adults is found in a variety of 
organs and in multiple normal cells [11]. However, vimentin 
expression increases during cancerogenesis [12]. In addition, 
vimentin is expressed in numerous cells of the tumor stroma, 
thus its expression in tumor stroma may reflect the conditions 
within the tumor microenvironment [13–15]. Vimentin was 
traditionally considered a marker of epithelial-to-mesenchy-
mal transition (EMT), the process whereby cells lose their 
epithelial characteristics and acquirea spindle-shape and the 
characteristics of mesenchymal cells. EMT is a characteristic 
phenomenon of cancer cells; associated with tumor infiltra-
tive growth, metastasis and greater resistance to chemo-
therapy [16]. However, vimentin is not only a cytoskeletal 
protein responsible for cell architecture and integrity, but 
also a participant in the regulation of cancer-related signal 
transduction pathways, such as Raf/14-3-3 and PI3K/AKT, 
as well asin the extracellular signal–regulated kinase (Erk) 
pathways responsible for invasiveness, motility, and cell mi-
gration. Vimentin is a crucial element of cell migration, inva-
sion, invadopodia development and metastases, and these 
processes are inhibited by vimentin downregulation [17]. 
Additionally, current data suggest the important function 
of vimentin in VEGF-driven angiogenesis, indicating the role 
of vimentin in tumor stroma rebuilding [18] its exploitation 
as a clinical target has achieved limited success and novel 
molecular targets are required.
High expression of vimentin in cancer cells is associated 
with a poor prognosis for patients with numerous types 
of neoplasms. Recent studies have also emphasized that 
elevated stroma vimentin expression correlates with short-
ened survival rates in colorectal cancer patients[19, 20].
Although the role of vimentin as a prognostic factor in 
ovarian cancer has not yet been established, preclinical 
studies have provided evidence that elevated vimentin 
expression is associated with platinum sensitivity which 
suggests a favorable prognosis [21, 22]. 
Objectives
The main aim of our research was to evaluate the impact 
of vimentin expression in ovarian cancer cells and in tumor 
stromaon the overall survival of patients with malignant 
ovarian tumors. Furthermore, we tried to determine whether 
vimentin expression correlates with selected elements of 
tumor stroma and pathologic characteristics of cancer. 
MATERIAL AND METHODS
Patient characteristics
The study material comprised 94 samples of malignant 
ovarian tumors collected from a group of women treated in the 
Department of Gynecology and Oncology of the Lukaszczyk 
Oncological Center, Bydgoszcz, Poland, during the period from 
2005 to 2010. The median patient age was 57 (range 25–86). 
The materials were obtained during primary cytoreductive 
surgery. The distribution of histopathological findings and 
FIGO stage of the disease are summarized in Table 1.The me-
dian patient follow-up was 41 months (range 0–160 months). 
Information on patients who died was retrieved from the 
Table 1. Distribution of histopathological findings and FIGO stage 
of the disease among patients included in the study
Histopathological diagnoses Number [%]
Serous adenocarcinoma 57 (61%)
Mucinous adenocarcinoma 5 (5%)
Endometrioid adenocarcinoma 11 (12%)
Clear cell adenocarcinoma 4 (4%)
Undifferentiated carcinomas 2 (2%)
Transitional cell carcinomas 3 (3%)
Adult granulosa cell tumors 10 (11%)
Borderline ovarian tumors 2 (2%)
Tumor grading system* Number [%]
G1 2 (2%)
G2 30 (36%)
G3 52 (62%)
FIGO stage of the disease Number [%]
FIGO I 20 (21%)
FIGO II 8 (9%)
FIGO III 66 (70%)
FIGO IV** 0
*Histopathological grading system was not applied for the granulosa cell 
tumors; **Patients with the disease classified as stage IV were not included in 
the study
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database of the Cuiavia-Pomerania regional office of the 
National Health System of Poland. This study received the 
approval of the Jagiellonian University Ethics Committee 
(Reference: KBET/89/B/2005 and DK/KB/CM/0031/447/2010), 
and all patients gave informed written consent. 
Immunohistochemistry 
The study was performed on a DakoLink48 apparatus, 
using the EnVision method, with EnVision™ Flex+ kit, Mouse, 
High pH (Link) (Dako/Agilent, K8002) and ready-to-use murine 
monoclonal antibody from Dako/Agilent Vimentin (IR630), 
clone V9. All immunohistochemical studies were performed 
on 4 μm thick sections taken from cancerous tumors fixed in 
4% formalin buffered and embedded in paraffin blocks. Paraf-
fin sections were placed on Knittel Glass adhesive slides and 
incubated for 2 hours in a chamber thermostat at 60°C. Prior to 
the automatic performance of the study, tissue sections were 
subjected to dewaxing followed by thermal epitope detection 
(HIER) in a PTLink device using EnVision™ FLEX Target Retrieval 
Solution, High pH (50x) (K8002). Finally, the preparations were 
dehydrated in a series of alcohols with increasing concentra-
tions and closed in a medium (Consul Mount, Thermo Shan-
don, USA). The method takes place at room temperature. Each 
time, a control preparation was added to the series of patient 
samples. Vimentin immunoreactivity was assessed within the 
cancer cells and the tumor stroma.The differentiation between 
stromal and cancer cells infiltrating the tumor stroma was as-
sessed based on cell morphology, and the assessment was per-
formed by an experienced pathologist (W.J.). In the case of can-
cer cells we used two types of immunoreactivity assessment: 
1) evaluation of the staining intensity, and 2) evaluation of 
the percentage of positive cells. Staining intensity in vimentin 
cancer cells was stratified into two groups: 1) low expression, 
including absent (0), minimal (1+) and moderate (2+) expres-
sion; and 2) high expression (3+). Vimentin quantitative expres-
sion in cancer cells was evaluated using the subjective method 
of the succeeding approximations assessing the percentage 
of vimentin positive cells. For our statistical analysis, we distin-
guished two study groups: 1) comprised of low quantitative 
vimentin expression (staining found in less than 30% of cells), 
and 2) comprised of high quantitative vimentin expression 
(vimentin expression present in more than 30% of cells). Vimentin 
expression in tumor stroma was assessed by staining intensity. 
Staining intensity was evaluated by subjective assessment in 
central and peripheral stroma using a four-degree scale: absent 
(0), minimal (1+), moderate (2+) and high (3+). The results from 
the central and peripheral stroma were averaged, and then the 
expression in the tumor stroma was assessed as either “low” 
when the results of the calculations were below and including 
2, or “high”when above 2. Stromal cellularity was evaluated 
by assessing the number of tumor stroma cells visible in the 
microscopic High Power Field (HPF) view. The quantity of tu-
mor stroma cells was evaluated subjectively in the central and 
peripheral stroma using a three-degree system: 1+, 2+ and 3+, 
and then the results from the central and peripheral stroma 
were averaged. Subsequently, the cellularity was assessed as 
either “low” when the results of calculations were below 1.5, or 
“high” when above and including 1.5. Immunohistochemistry 
studies and tumor analyses were performed by an experienced 
pathologist (W.J.), who was blinded for the results of patients’ 
overall survival. Representative images of vimentin staining 
are presented in Figure 1. 
Statistical analysis
The data were compared using achi square test. 
However, if expected cell frequencies were below five-
forthe 2 x 2 contingency table, then the Fisher exact test 
was performed. Survival analyses were conducted using 
Kaplan-Meier survival curves. 
RESULTS
Vimentin expression and patient OS
Table 2 summarizes the results of the analysis of vimen-
tin expressionand stromal cellularity.
High cancer cell vimentin expression intensity was asso-
ciated with significantly prolonged survival. Patients whose 
cancer cells had high vimentin expression intensity had 
a median OS of 100 months (range 0–160) compared with 
32 months (range 0–160) for the patients with low vimentin 
expression intensity in cancer cells (P = 0.007) (Fig. 2A).
Patients who suffered from tumors with high quanti-
tative vimentin expression in the cancer cells (up to and 
including 30% of cells) had a significantly longer median OS 
(49 months, range 0–160) compared with those patients with 
low quantitative vimentin expression in the cancer cells (be-
low 30% of cells; 28 months, range 3–134; P = 0.02) (Fig. 2B).
Patients with low vimentin expression in the tumor 
stroma hada prolonged OS when compared with patients 
with high expression. However, thatresult did not achieve 
a level of statistical significance (117 months, range 0–160 vs 
37 months, range 0–148 respectively, P = 0.06; Fig. 1C). The 
cellularity of the tumor stroma had no impact on patients’ OS. 
Relationship between tumor and stroma 
vimentin expression, and the correlation with 
stroma cellularity
High tumor cell vimentin expression intensity was asso-
ciated with significantly higher vimentin stromal expression. 
There wasno relationship between vimentin quantitative 
expression in cancer cells and vimentin expression in the 
tumor stroma (Tab. 3). High vimentin expression in the 
tumor stroma was correlated with high cellularity of the 
tumor stroma. Vimentin expression in cancer cells was not 
associated with tumor stroma cellularity (Tab. 4). 
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Vimentin expression and clinicopathologic 
features of ovarian malignancies
Vimentin expression (in both cancer cells and tumor stro-
ma) did not differ between the histopathological types of ovar-
ian malignancies (Tab. 5). Similarly, there were no differences 
in vimentin expression with regard to the FIGO stage of the 
disease and tumor grade (Tab. 6). Non-differentiated (2 tumors), 
transitional cell carcinomas (3 tumors), borderline tumors 
(2 tumors) and G1 neoplasms were all excluded from the analysis 
of clinicopathologic features due to the low number of subjects.
Figure 1. Representative pictures of vimentin expression in analyzed ovarian malignancies. A) and B) Serous adenocarcinoma of the ovary showing 
absent vimentin expression in cancer cells (white arrows). Vimentin expression is present in the tumor stroma (yellow arrows). Magnification: 
x200 and x400 for A) and B) respectively; C) and D) Serous adenocarcinoma of the ovary presenting with minimal vimentin expression in cancer 
cells (white arrows). Vimentin expression is present in the tumor stroma (yellow arrows). Magnification: x200 and x400 for C) and D) E) and F) 
Endometrioid adenocarcinoma of the ovary showing moderate vimentin expression in cancer cells (white arrows). Magnification: x200 and x400 
for E) and F) respectively; G) and H) Serous adenocarcinoma of the ovary with high vimentin expression in cancer cells (white arrows). Vimentin 
expression is also found in the tumor stroma (yellow arrows). Magnification: x200 and x400 for G) and H) respectively
A B
C D
E F
G H
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DISCUSSION
Numerous studies have revealed high vimentin expres-
sion as a negative prognostic factor in human neoplasms. In 
the case of colorectal cancer, it was shown that both tumor 
cell expression and tumor stroma expression were associat-
ed with poor patient prognosis [19, 20, 23]. In a meta-analysis 
by Du et al., vimentin expression indicated a shortened OS 
and disease-free survival (DFS), lymph node metastases, 
and a higher TNM stage of colorectal cancer patients [23]. 
Similarly, a meta-analysis by Yin et al., of 1.598 patients with 
gastric cancer,has shown vimentin expression to be a prog-
nostic factor of shortened survival [24]. Meta-analysis studies 
evaluating the expression of vimentin in non-small cell lung 
cancers have also shown the negative predictive value of vi-
mentin expression. Similarly, vimentin expression was asso-
ciated with poor prognoses for patients with breast cancer, 
cervical cancer, lung adenocarcinomas, oral cancers, bladder 
cancer, and soft tissue leiomyosarcomas [23, 24]. However, 
not all studies are in full agreement with these reports of the 
negative prognostic role of vimentin in cancer patients. In 
a study by Zou et al. involving more than 500 patients with 
early stage endometrioid cancers, vimentin expression was 
associated with prolonged survival [25]. 
There is sparse data on vimentin tumor expression as 
a prognostic factor in cases of ovarian cancer. We have iden-
tified only one study, by Li et al., which includes analysis of 
43 cases of EOC. In their univariate analysis, the authors as-
sociate tumor vimentin expression with significantly short-
ened disease-free survival, whereas in their multivariate 
analysis the association between vimentin expression and 
disease-free survival was insignificant. Vimentin expres-
sion did not influence EOC patients’ OS, in the univariate or 
multivariate analyses [26]. In our study, we found that both 
high quantitative vimentin expression and a high intensity 
of vimentin expression in cancer cells were associated with 
a better prognosis. This may be explained by the role of vi-
mentin in the regulation of cancer cell platinum-resistance, 
as this is one of the most important factors influencing 
patient prognosis [27]. In their study, Huo et al. used two 
pairs of ovarian cancer cell lines [21]. The authors revealed 
that the downregulation of vimentin expression increased 
resistance to cisplatin. Furthermore, their study showed that 
the upregulation of vimentin expression markedly increased 
cisplatin sensitivity. The study by Huo et al. is not the only 
report showing downregulation of vimentin as an indicator 
of drug resistance in patients with ovarian cancer. Similar 
results were obtained by Jin et al. where downregulation of 
vimentin was found among cisplatin-resistant EOC cells [22]. 
Additionally, Kanakkanthara et al. have shown that low 
vimentin expression is associated with resistance to microtu-
bule stabilizing agents, such as peloruside A and laulimalide 
[28]. Taken together, these data suggest that platinum sen-
sitivity related to the expression of vimentin in cancer cells 
is responsible for the prolonged survival of ovarian cancer 
patients. 
Interestingly, Huo et et al. have revealed that vimentin 
knockdown cells formed spheroids and they destabilized 
both anchoring junctions and tight junctions. Additionally, 
vimentin-downregulated cells acquired stem cell-like charac-
teristics and showed increased expression of stem cell mark-
ers [21]. There is a close relationship between cancer stem cell 
(CSC) phenotype sand cells undergoing EMT, and both are 
associated with chemoresistance [16]. These findings may in-
dicate that despite acquiring EMT/CSCs features, ovarian can-
cer cells with higher vimentin expression are characterized by 
improved sensitivity to platinum-based agents. Thus, an as-
sociation between vimentin downregulation, EMT, cancer 
stem-cells phenotypes, and chemoresistance is particularly 
intriguing and demands further investigation. 
We also found that patients with high vimentin expres-
sion in the stroma of malignant ovarian tumors had short-
ened survival compared with patients with low vimentin 
expression, however, this difference did not reach the level 
of statistical significance. To the best of our knowledge, 
our study is the first to report vimentin expression in the 
stroma of the ovarian neoplasm. We did identify studies 
showing that a poorer prognosis is related to stromal vi-
mentin expression;but those studies concerned patients 
with colorectal and prostate cancers [20, 29]. The tumor 
stroma mainly consists of resident fibroblasts, endothe-
lial cells, pericytes, leukocytes, and extra-cellular matrix. 
Within the tumor stroma, the CAFs are the most promi-
nent cell type. Vimentin is one of the markers used toiden-
tify CAFs. However, vimentin staining was also noted in 
normal fibroblasts present in the tumor stroma and in the 
tumor stroma myofibroblasts (activated fibroblasts) [13]. 
In addition, vimentin staining was present on the cells of 
Table 2. The results of vimentin expression analyses and tumor 
stroma cellularity
Vimentin expression intensity in cancer cells N [%]
Low 65 (69%)
High 29 (31%)
Vimentin quantitative expression in cancer cells N [%]
< 30% 16 (17.0%)
≥ 30% 78 (83.0%)
Vimentin expression intensity in stroma N [%]
Low 14 (15%)
High 80 (85%)
Stromal cellularity N [%]
Low 35 (37.6%)
High 58 (62.4%)
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vascular origin, such as the endothelial cells co-labeled with 
CD31 and pericytes [14]. Further, vimentin may be secreted 
into extracellular space by activated macrophages [15]. Thus, 
there are numerous putative sources of tumor stroma vi-
mentin expression. Multiple studies support the role of CAFs 
in ovarian cancer development and progression; however, 
the role of normal fibroblasts and myofibroblasts is not fully 
elucidated [13].Additionally, current studies indicates that 
there are various subpopulations of CAFs, and that there are 
significant differences in their impacts on tumor growth [30]. 
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Figure 2. Survival analyses according to vimentin expression. A) Patients with high vs low vimentin expression intensity in cancer cells; B) Patients 
with high (up to and including 30% of cells) vs low (below 30% of cells) vimentin quantitative expression in cancer cells. C) Patients with low and 
high vimentin expression in the tumor stroma
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Although high tumor microvascular density (MVD) is known 
as apoor prognostic indicator in many human neoplasms, 
in general, MVD assessed by endothelial staining with 
an anti-CD31 antibody does not influence ovarian cancer 
patient prognosis [31]. High vimentin expression may also 
reflect increased pericyte coverage of tumor blood vessels 
[14]. On the one hand, tumor vessels with high pericyte 
coverage build up a more stable vasculature leading to 
increased tumor growth. On the other hand, high pericyte 
coverage inhibits tumor hematogenous metastases and is 
associated with better prognoses for cancer patients [32]. 
Recent findings suggest that the spread of ovarian cancer by 
the hematogenous route in patients is far more significant 
than previously thought [33].Taken together, these findings 
show a trend towards a poor prognosis for patients with 
tumors presenting with high vimentin stromal expression. 
However, considering the variety of vimentin positive cells 
within the tumor stroma, further studies are needed for 
a better identification of these cells. 
Recently, attention has been paid to interactions be-
tween cancer cells and the tumor stroma structure. In this 
paper, we have evaluated the relationships between vi-
mentin expression in cancer cells with vimentin stromal ex-
pression and tumor stroma cellularity. The idea behind this 
Table 3. The relationship between vimentin expression in cancer cells with vimentin stromal expression 
Low vimentin expression intensity 
in cancer cells
High vimentin expression 
intensity in cancer cells
Low vimentin expression intensity in stroma 14 (15%) 0 (0%)
P = 0.0006
High vimentin expression intensity in stroma 37 (39%) 43 (46%)
Low vimentin expression in 
cancer cells (< 30% of cells), N [%]
High vimentin expression in 
cancer cells (≥ 30% of cells), N [%]
Low vimentin expression intensity in stroma 5 (5%) 9 (10%)
P = 0.52
High vimentin expression intensity in stroma 21 (22%) 59 (63%)
Table 4. The relationship between vimentin expression and stroma cellularity
Low vimentin expression intensity in cancer cells High vimentin expression intensity in cancer cells P–value
Low stromal cellularity 21 (22%) 14 (15%)
P = 0.16
High stromal cellularity 44 (47%) 15 (16%)
Low vimentin expression in cancer cells  
(< 30% of cells), N [%]
High vimentin expression in cancer cells  
(≥ 30% of cells), N [%]
Low stromal cellularity 13 (14%) 22 (23%)
P = 0.15
High stromal cellularity 13 (14%) 46 (49%)
Low vimentin expression intensity in tumor 
stroma, N [%]
High vimentin expression intensity in tumor 
stroma, N [%]
Low stromal cellularity 11 (11%) 24 (26%)
P = 0.0015
High stromal cellularity 3 (3%) 56 (60%)
Table 5. The relationships between vimentin expression and histopathological types of the disease
Vimentin expression 
intensity in the tumor cells
Serous 
adenocarcinoma
Mucinous 
adenocarcinoma
Clear-cell 
adenocarcinoma
Endometrioid 
adenocarcinoma
Adult granulosa 
cell tumors P-value
Low 37 (66%) 5 (100%) 3 (75%) 6 (55%) 7 (70%)
P = 0.48
High 19 (34%) 0 (0%) 1 (25%) 5 (45%) 3 (30%)
Vimentin expression in 
cancer cells (percentage of 
cells)
Serous 
adenocarcinoma
Mucinous 
adenocarcinoma
Clear-cell 
adenocarcinoma
Endometrioid 
adenocarcinoma
Adult granulosa 
cell tumors
Low (< 30% of cells), N [%] 11 (20%) 1 (20%) 0 (0%) 2 (18%) 1 (10%)
P = 0.84
High (≥ 30% of cells), N [%] 45 (80%) 4 (80%) 4 (100%) 9 (82%) 9 (90%)
Vimentin expression 
intensity in tumor stroma
Serous 
adenocarcinoma
Mucinous 
adenocarcinoma
Clear-cell 
adenocarcinoma
Endometrioid 
adenocarcinoma
Adult granulosa 
cell tumors
Low 7 (8%) 0 (0%) 0 (0%) 1 (1%) 4 (5%)
P = 0.11
High 50 (57%) 5 (6%) 4 (5%) 10 (12%) 6 (7%)
18
Ginekologia Polska 2019, vol. 90, no. 1
www. journals.viamedica.pl/ginekologia_polska
project was to investigate vimentin as an indicator of stroma 
remodeling. We have shown that cancer cell vimentin ex-
pression strongly correlates with a degree of tumor stroma 
vimentin expression. Vimentin may be upregulated by a va-
riety of factors, including cancer-related growth factors, such 
as the transforming growth factor beta (TGF-beta) and the 
epidermal growth factor (EGF) [34]. Thus, vimentin stromal 
expression may merely reflect tumor-stroma interactions, 
whereas cancer cells may influence the stroma compart-
ment. However, vimentin stromal expression may also be 
explained as a result of specific tumor microenvironmen-
tal conditions. For instance, it has been shown that tumor 
hypoxia through hypoxia-inducible factor-1 (HIF-1) is one 
of the key elements upregulating the expression of vimen-
tin [35]. In our observations, vimentin expression in tumor 
stroma was correlated with stroma cellularity. This suggests 
that vimentin is responsible for, or is just an indicator of, 
higher stroma infiltration by CAFs and leucocytes. Although 
we did not observe a correlation between stroma cellular-
ity and the patients’ prognoses, EOC with well-developed 
stroma are characterized by poor prognoses [4]. However, 
recent studies highlight that the stroma content differs 
significantly between various cases of EOCs. Additionally, 
there are various subpopulations of fibroblasts infiltrating 
tumor stroma. For instance, Givel et al., have shown that the 
CAF-S1 subset, when present in the stroma of high grade 
serous ovarian carcinoma has more potent immunosup-
pressive characteristics when compared with other subsets 
of CAFs. Additionally, there are various populations of TILs, 
and while regulatory T-cells indicate poor survival, cytotoxic 
T-cells indicate better prognoses for cancer patients [9]. 
These findings suggest that the prognosis of cancer patients 
is more related to the type of stroma infiltrating cells, and 
less to their number [30]. 
CONCLUSIONS
We conclude that vimentin expression in cancer cells 
may be used as a potential prognostic factor of the overall 
survival of patients with ovarian malignancies. Additionally, 
due to the interactions between vimentin expression in 
cancer cells with vimentin stromal expressions and stroma 
cellularity, we suggest vimentin may participate in the for-
mation of tumor stroma.
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